Project Alert

Thermo Fisher Scientific has opened a $90 million, 50,000-square-foot viral vector manufacturing facility in Lexington, Massachusetts. The contract development and manufacturing organization expects to create more than 200 jobs at the site, which will support development, testing and manufacturing for viral vectors, the inactivated viruses used to deliver gene therapies. According to the company the new site will help address a "bottleneck" in manufacturing viral vectors. Alert readers will recall that Thermo Fisher paid $1.7 billion earlier this year for viral vector contract manufacturer Brammer Bio. Learn More

Eli Lilly and Company this week unveiled its first shared innovation lab, located in South San Francisco, designed to speed the discovery of innovative medicines through collaboration with local biotech companies. Lilly Gateway Labs will offer companies direct access to Lilly scientists, team members and executives, as well as exposure to Lilly's scientific and functional expertise. With over 65,000 square feet of space, Lilly Gateway Labs offers 32 state-of-the-art, flexibly designed private lab modules. Each module includes lab space for six to eight scientists, office space, and workstations. Learn More

Singapore has announced that its research and development hub Biopolis will be expanded to meet the needs of biotechnology start-ups. Phase 6 of Biopolis will add a further 376,000+ sq. ft. (35,000 sq m) of business park space for biomedical sciences research and supporting activities and 64,000+ sq. ft. (6,000 sq m) for office and retail use. This will include 21,000+ sq. ft. (2,000 sq m) of fitted-out laboratory spaces with lab benches, waste drainage and exhaust provisions. Biopolis currently houses nine A*Star research institutes and over 60 companies, with thousands of employees undertaking research, clinical trials and commercialization of new scientific discoveries. Learn More

Novartis has opened a new manufacturing facility for cell and gene therapies in Switzerland. In addition to manufacturing areas for novel CAR-T cell therapies, the new building also hosts the production of innovative, difficult-to-manufacture solid dosage forms such as tablets and capsules. In September 2019, the first clinical production of a cell and gene therapy batch was successfully completed. The $90 million facility is on track to begin commercial production of its cell therapy Kymriah for cancer in 2020. The Swiss facility, as well as a separate French site also being expanded, are central to Novartis's plans to transform Kymriah from a modest $250 million-per-year seller into a $1 billion blockbuster as European demand rises. Learn More

Plans are moving forward for another Bay Area biotech campus. Alexandria Real Estate Equities is transforming a chunk of property in San Carlos, California into a 1.6 million-square-foot biotech campus. According to the San Francisco Business Times, the real estate development company submitted plans for its proposed biotech campus. Alexandria Real Estate Equities intends to turn the space into six new buildings, each about five to seven floors for biotech companies to use. In addition to the buildings, the site will also include an amenities structure, parking garages and a small park, according to the Business Times. Learn More

Horizon Therapeutics has announced the opening of its new office in South San Francisco, located at 2 Tower Place, 12th floor. The 20,000 square-foot facility will feature laboratory space that will enable formulation and process development for manufacturing, as well as bioanalytical method development and other R&D functions. Horizon plans to add new positions in bioanalysis, clinical research, pharmacology, manufacturing and business development during the next year. Learn More

Maravai LifeSciences has unveiled its new $40 million headquarters this week in San Diego, California. In addition to doubling overall manufacturing capacity by adding a 50,000 sq. ft. manufacturing facility, TriLink BioTechnologies, a Maravai LifeSciences company  whose headquarters will also be housed in the new facility, has added five new Current Good Manufacturing Practice (cGMP) suites, for a total of six, that can be specifically tailored for customer drug development campaigns including scaleup for Phase I clinical trials. The new 105,000-square-foot facility houses the company's current local staff of more than 150 and can accommodate growth to more than 350 R&D, commercial and manufacturing employees. Learn More

Eli Lilly and Co. will invest $400 million in its manufacturing facility in Indianapolis, an upgrade that will lead to an additional 100 highly skilled jobs at the Indianapolis-based drug manufacturer. The money will go to enhancing the existing facilities at the Lilly Technology Center campus, which manufactures insulin. It will also help Lilly increase its capacity to make other diabetes medicine, company officials said in a news release. In addition to insulin, Lilly makes 10 non-insulin diabetes drugs. Company officials said that the money announced this week would go to improving the company's syringe-filling, device assembly and packaging operations. Learn More

Arkuda Therapeutics, a biotechnology company developing therapies to change the trajectory of neurodegenerative disease, has signed a 10,819 square foot lease at Arsenal Yards' new state-of-the-art life science lab space. The biotech becomes the latest in a growing number of emerging biopharma companies to relocate from Kendall Square in Cambridge to Watertown's biotech cluster. Arsenal Yards boasts more than one million square feet of development including lab and office space. Learn More

Fujifilm Diosynth Biotechnologies has announced the expansion of its gene therapy services with the addition of dedicated process and analytical development laboratories. As part of a capital investment of approximately $120 million in the gene therapy field by FUJIFILM Corporation, an investment of approximately $55 million USD will be made to establish a new Gene Therapy Innovation Center adjacent to the existing state-of-the-art cGMP gene therapy manufacturing facility in College Station, Texas. The Gene Therapy Innovation Center will be approximately 60,000 square feet and house state-of-the-art upstream, downstream and analytical development technologies. The facility will be operational in the fall of 2021. Learn More

CMO CMIC has leased 233,000 sq. ft. at 270 Prospect Plains Rd. in Cranbury, NJ. The site will be used for office, research and development, production, packaging, manufacturing, warehousing and distribution. The deal involved negotiating a lease termination with an existing tenant, Sun Pharmaceutical, and arranging for the purchase of in-place research and development infrastructure. Learn More

Rentschler Biopharma is taking the first step in the expansion project to grow its U.S. footprint and establish a Center of Excellence in North America, putting into operation a 500L single-use bioreactor for the 93,000 square foot facility near Boston, MA. The XDR-500 bioreactor, with a working volume of 100-500 L, is planned to be client-ready in mid-2020 and is currently being prepared for technology transfer. Further expansion planning includes another building for large-scale manufacturing, which will also be single-use bioreactor manufacturing as well as lab capacity for new modalities. Learn More

Takeda this week opened a new plant in Singen, Germany that will manufacture the company's experimental dengue vaccine, which is newly supported by Phase 3 results that appear to show the shot is effective in guarding against the mosquito-borne viral disease. The biopharma has invested more than $140 million over the past three years as it built the facility, which will employ as many as 200 people once operational. Takeda first began construction in 2016, and the plant is now ready for packaging production. End-to-end production of the vaccine, known as TAK-003, will be ready nearer to when Takeda expects to secure licensure of the drug. Learn More

AstraZeneca says it will establish centers for drug research and artificial intelligence development in China. The biopharma giant has also set up a $1 billion fund to foster biotech innovation in that country. The move will see the AstraZeneca found a global R&D center in Shanghai's central Jing'an district. The company currently operates R&D centers at its Cambridge, UK, headquarters as well as at sites in Maryland and Sweden. The new China facility will carry out R&D for innovative drugs, with the focus being on diseases that are prevalent in China. The site will bring AstraZeneca's R&D headcount in China to 1,000 people. The industry leaders says it has no plans to co-locate all China R&D facilities. Learn More

Azurity Pharma, formed in May has picked 8 Cabot Road in Woburn for its new expanded corporate headquarters. The company will relocate from Presidential Way to 14,627 square feet within the 60,000-square-foot 8 Cabot Road office building. Azurity specializes in drug delivery systems including ones optimized for children and the elderly. The company was formed in May when CutisPharma acquired Silvergate Pharmaceuticals and rebranded the combined company. Along with the Woburn headquarters, Azurity has a manufacturing facility in Wilmington. Learn More

San Diego will create California's first "capacity bank" for water and sewer, allowing breweries and biotech firms to cheaply buy excess water and sewer capacity from former factories. The City Council unanimously approved the capacity bank, calling it an innovative idea that will create jobs and help the city avoid expensive expansions of its sewer and water infrastructure. The council also unanimously approved a companion proposal that geographically expands and softens the qualifications for the city's "guaranteed water" program, which ensures local firms access to water during droughts or other kinds of shortages. Learn More

Prelude Therapeutics, one of the biotech companies growing up in the state-backed Delaware Innovation Space at the DuPont Experimental Station just outside Wilmington, has pledged to hire up to 49 biotech professionals and find larger quarters in the state, to win a commitment for taxpayer financing. Founded in 2016, Prelude plans to invest $5 million in its new headquarters, state officials said in a statement. The state-funded Council on Development Finance has agreed to give Prelude $830,000 in Delaware Strategic Fund grants, based on the company's meeting its hiring goals to boost its current 32 workers to 81 over the next three years, including scientists and "skilled associates." Learn More

Teesside University in the United Kingdom has officially opened its $28 million National Horizons Centre, which it believes will catalyze talent development and increase engagement between research, teaching and industry. The university already has collaborative partnerships with companies such as Fujifilm Diosynth Biotechnologies and GlaxoSmithKline, which officials say will ensure a foundation for the development of industry-relevant training and work-ready graduates. Among the new equipment featured at the state of the art center are glass and steel bioreactors and bioreactor controllers from Applikon. Learn More

WuXi Biologics plans to build a four-storey vaccine manufacturing plant which will bring a further 200 jobs to Dundalk, Ireland. WuXi has already commenced building a $360 million factory on their Mullagharlin Road site in Dundalk. A new company called WuXi Vaccines Ireland submitted the plans for an additional 167,000 sq. ft. of new buildings to Louth County Council, to be built to the north of the site adjacent to the Mullaharlin Road, earlier this month. The newly-proposed facility will comprise of one main integrated administration, manufacturing and warehouse building with some ancillary buildings. Learn More

Anpac Bio has signed a 10-year lease on a newly constructed 6,724-square-foot office at the Spring House Innovation Park in Pennsylvania. The company, founded in 2008, had been looking to expand to the East Coast. Anpac, which will keep its office in San Jose, will bring 10 of its 100 employees to the Spring House complex in the spring. Alert readers mights recognize the name of the industrial park, it is home to a number of other biopharma industry suppliers and end users including Chromatan. Learn More

TriPharm Services, a new CDMO, is commissioning a new specialized manufacturing operation utilizing the latest isolator manufacturing equipment. The facility, located at 627 Davis Drive in Morrisville, NC, and totaling 32,000 square feet, will offer four isolator filling suites and the highest level of control available for Grade A processing of client biologic and small molecule products. Featuring state-of-the-art equipment, the facility has eight multi-purpose cleanrooms to support manufacturing operations, along with modern, specialized utility systems to scale to client requirements. The state-of-the-art equipment and facility are set to be fully operable in the second quarter of 2020. Learn More

Sanofi this week unveiled a roughly 100,000-square-foot biologics manufacturing plant in Framingham, Massachusetts, touting the facility as a key cog in a broader plan to retool its production base.  The new site will use continuous manufacturing rather than traditional batch processing, a change the industry has generally been reluctant to make. Relying on single-use equipment, the plant will use less energy and chemicals, executives said, while boosting productivity versus a typical set-up. Sanofi has spent about $320 million over the past five years on the Framingham facility. The plant is expect to be approved by the FDA late next year. Learn More

The Delft University of Technology in the Netherlands has launched Planet B.io, an incubator aimed at scaling up technology developed by industrial biotech startups. Planet B.io is based at the campus of the Delft University of Technology and contains a total of 32,000 sq. ft. of office and lab space for small biotech companies. To help startups scale up, there is a shared pilot production facility where companies can test their technology with the help of industrial mentors. The incubator is just one of a few that are focusing exclusively on industrial biotech, which can have different requirements such as large-scale bioreactors and fermentation tanks. Learn More

The University of Maryland BioPark and developer Wexford Science & Technology have revealed updated plans to the Baltimore City Planning Department's Urban Design & Architecture Advisory Panel (UDAAP) for a $200-plus million, 10-story, 333,000 sq. ft. office and biotech building at the northwest corner of Martin Luther King Blvd. and W. Baltimore St. in South Baltimore, Maryland. The new building, which is being called 4 MLK, is Phase One of a two-phrase project that will redevelop a Poppleton/Hollins Market block that borders Martin Luther King Blvd., W. Baltimore St., W. Fayette St., and N. Fremont Ave. Learn More

Sanofi has opened a new UK Headquarters, based at Thames Valley Park in Reading, Berkshire. The new 70,000 square ft. office facility marks a $45 million investment to Reading and will be the new base for 500 of the 1,200 Sanofi employees in the UK. The company revealed that it is actively seeking to recruit at least 50 new roles in the coming months, in addition to ten graduate students via its new Aspiring Leaders program. The company welcomed Matt Hancock, secretary of state for health and social care, to open the "state of the art" facility, alongside Paul Hudson, chief executive officer of Sanofi and Hugo Fry, UK's managing director. Learn More

With pastel-coloured walls, neon decorations and plush sofas, a co-working space in Biopolis can be mistaken for a cafe or a blogshop's retail outlet. But NSG BioLabs, fitted with a sterile lab and high-tech equipment, is a 15,000 sq ft co-working space for biotech start-ups. To be launched next month, it looks set to play host to some of the nation's brightest minds. The facility will be an incubator for small biotech start-ups, ranging from those with just one to two researchers to those with 20 to 30 people. It has 120 desks, 96 lab benches, eight office suites and six meeting rooms. Its founder, 36-year-old Daphne Teo, decided to set up the premises after the biotech company she co-founded struggled to find a space to operate in. Learn More

Janssen this week officially opened its new manufacturing building in Ringaskiddy, Co. Cork. The company has operated a biopharmaceutical supply chain facility in Ringaskiddy since 2005. The expansion of the roughly 100-acre biomanufacturing site increases the company's production capacity by an additional 205,000 sq. ft. and creates 200 new full-time jobs. Approximately 450 people were employed on-site during the two-year construction project. Learn More

GSK has officially opened a new biologics manufacturing plant at its existing site in Rockville, Maryland. The $139 million facility was built to add manufacturing capacity for GSK's Benlysta, to that end it features an additional 2 x 10,000L of capacity. The scope of the project included the demolition of existing suites and the engineering, installation and validation of new equipment. The unveiling of the Maryland site comes just about a week after GSK officially opened a new $120M in biopharma plant at the drugmaker's manufacturing site in Upper Merion, Pennsylvania, just outside of Philadelphia. Learn More

Cellectis will tap Lonza to manufacture its experimental CAR-T cell therapies for blood cancers, in an effort to expand its product supply for clinical studies. Lonza will produce the therapies at its facility in Geleen, Netherlands. Before signing the deal with Lonza, Cellectis announced plans in March for in-house manufacturing sites in Raleigh, North Carolina and Paris, France. Together the two facilities currently under construction will give Cellectis nearly 100,000 square feet of manufacturing space for both commercial and clinical use. No financial details of the deal were disclosed by the companies. Learn More

LabCentral, the biotech incubator at 700 Main Street in Cambridge, MA, that has nurtured dozens of startups in a shared working space since 2013, plans to roughly double in size in two years with a new 100,000-square-foot facility in the heart of Kendall Square. But instead of providing laboratory equipment for scientists to do early-stage research, the new outpost will help startups that have cleared that hurdle to develop potential drugs that the firms eventually hope to test in clinical trials. This comes after the local government announced a $5 million grant to LabCentral. Learn More

New York City's life sciences community continues to boom as Deerfield Management Company, in partnership with LifeSci NYC and the New York City Economic Development Corporation, have announced an initial $635 million investment to create a transformative life sciences campus in the Big Apple, and a total commitment of $2 billion by 2030. The home for the future campus is a facility on Park Avenue that provides more than 300,000 square feet of space, of which more than 200,000 square-feet will be wet lab capable, to support healthcare and biotech start-ups and growing companies that work on cutting-edge R&D to treat diseases and chronic conditions. The campus is expected to open in early 2021. Learn More

GSK has announced a $120 million investment to expand its manufacturing facility in Upper Merion, Pennsylvania. The newly outfitted manufacturing space is made to be more flexible through the use of single-use bioreactors and disposable bioprocessing components. A new analytical lab is also part of the facility, and the processes associated with quality and commercial testing have been streamlined to ensure medicines are ready for patient use as soon as possible. By bringing together the R&D and manufacturing teams in one facility in Upper Merion, GSK plans to achieve increased synergy and efficiency. Learn More

JLL has announced it recently completed a lease for 185,000 square feet of space at the 433-acre Bristol-Myers Squibb Hopewell campus with PTC Therapeutics. Located at 311 Pennington-Rocky Hill Road in Hopewell, the property includes an existing state-of-the-art biologics production facility, and supporting research and operations buildings. PTC Therapeutics' long-term lease will occupy Buildings 9, 10, 12, 13 and a portion of Building 18 at the Princeton West campus. PTC plans to further develop the biologics facility to support gene therapy production, and foster innovation and employment in the community. Learn More

Pfizer has paid about $19 million for the land and building near the intersection of I-40 and I-540 in Durham, North Carolina where it will consolidate its clinical gene therapy production. It will start construction on retrofitting it next year and expects to complete the work in 2022, at about the same time the lease expires on its current clinical supply facility in Chapel Hill. Pfizer acquired that facility via its 2016 Bamboo Therapeutics deal.  The new operation in Durham, called the Advanced Therapy Medicinal Product (ATMP) facility, will double Pfizer's clinical manufacturing capacity in gene therapy and will include two drug substance suites, a single drug product suite and labs. Learn More

WuXi Diagnostics, a one-year-old joint venture between New WuXi Life Science Investment Limited and Mayo Clinic, has confirmed that it plans to open a "research and diagnostic testing development facility" in downtown Rochester, Minnesota ... "to accelerate esoteric diagnostic product development, and bring more personalized and accurate clinical diagnosis services for global patients." The new facility will be located on the third floor of the new One Discovery Square complex on the corner of Fourth Street and Second Avenue Southwest. This follows a WuXi Diagnostics building permit filed in Rochester in April for a $543,000 tenant space project. Learn More

All employees at the Irish manufacturing arm of biopharma giant Roche in Co Clare Ireland will be made redundant by next June. Some 132 workers were employed at the Clarecastle plant at the end of last year and the directors state that decommissioning works will commence next year and continue to 2023. Roche originally announced in 2016 that it was to close the plant at Clarecastle after it failed to secure a buyer for the site. The facility is currently in the process of a phased closure and the directors state this will be complete by mid-March 2020. Learn More

Activation Capital, a nonprofit affiliated with the 34-acre VA Bio+Tech Park, has filed plans with the city of Richmond to build a six-story, 100,000-square-foot research building at 706 E. Leigh St. The building will occupy a roughly 2-acre block bounded by East Jackson, East Leigh, North Seventh and North Eighth Streets. Plans also show a 740-space parking deck. The project  awaits city approval. The property is already zoned with the same designation as other properties in the park, meaning it likely won't require a rezoning or special-use permit. Learn More

Backed by venture capital firm Pillar, Petri has a three-year $15 million commitment to back companies developing new biotech applications, along with the enabling technologies to bring these products to market. Pillar has already invested in a couple of companies that show the potential promise of new biotech research coming from Boston-based universities, like Boston University, Harvard and the Massachusetts Institute of Technology. Over time, the accelerator expects to have 10 to 20 companies in each market segment as the program expands. In addition to checks of at least $250,000 the Petri accelerator has lab and office space available for each company. Learn More

Pfizer has made public plans to establish a digital research hub with a focus on artificial intelligence and big data analytics in Thessaloniki, Greece. The Thessaloniki hub is part of a planned multinational network of digital research centers to develop technology that can be incorporated into Pfizer's development pipeline of medicines and vaccines. The biopharma giant expects the facility, the first of six, to become operational in 2020, providing up to 200 jobs. The recent announcement comes as a surprise to some due to the lack of biopharma on the island nation. However, Pfizer CEO Albert Bourla is a native of Greece, specifically Thessaloniki, Greece. Learn More

An India-based subsidiary of Sanofi said it will sell a manufacturing plant in Ankleshwar, Gujarat, to Advent International's Zentiva for about $37 million. The site is Sanofi's oldest manufacturing facility in India and produces medications including Combiflam, Allegra and Amaryl. Production of those products will be moved to other sites including in Goa, according to a Sept. 11th Sanofi release posted to India's stock exchange. The agreement builds on a much larger deal from last year, when Advent paid $2.1 billion, for Sanofi's European generics business, Zentiva. Now, a Zentiva unit in India is taking over the Ankleshwar site, which manufactures more than 6 billion tablets a year. Learn More

The Rock Creek Property Group has secured a $34 million loan for the conversion of a former manufacturing facility in Gaithersburg, Md., into a life science property. The property, built in 1973, sits on a 13-acre plot and will be converted into a 120,000 sq. ft. Class A life science building outfitted for one tenant. Rock Creek purchased the former manufacturing facility - at 700 Quince Orchard Road in Gaithersburg - from DRS Solutions in 2015 for just $5 million. The speculative conversion will establish the first floor of the building as a parking garage, and the build out and business plan will aim to house just one tenant, although it "breaks nicely from two to four ," Learn More

The UC Santa Cruz Genomics Institute is moving off campus and into the middle of a growing biotech hub on the city's westside. In a new 11,000-square-foot headquarters in a renovated office building at 2300 Delaware Ave., the Genomics Institute is hoping to find firm footing for its work in Santa Cruz's growing biotech corridor. Biotech incubator Startup Sandbox, a university-affiliated nonprofit, is just blocks away on Natural Bridges Drive. Budding biotech startups Claret Bioscience, NantOmics and Ontera are just around the corner. Prior to this summer, the institute was spread out across five sites on the sprawling university campus. Learn More

Morgan Sindall Construction has won a $23 million contract to build a new headquarters for Eli Lilly and Company in Basingstoke, UK. Located within the Basing View Enterprise Zone, the 45,000 sq ft five-story commercial building will provide Grade A workspace and a new home to the biopharma giant. The main contractor is carrying out the work for Basingstoke and Deane Borough Council, and Morgan Sindall Group sister company, Muse Developments. Designed by architect TP Bennett, the building will be owned by the borough council and will be the second-largest commercial asset in its portfolio. Learn More

The Westchester County Industrial Development Authority has given preliminary approval for a tax exemption on a $38.2 million biotech project in Ardsley, New York. BioMed Realty plans to complete two shell buildings at 430-440 Saw Mill River Road, next to the Accorda Therapeutics labs and offices on its Ardsley Park campus. The developer says it is targeting small life science companies that cannot afford the costs of outfitting expensive labs. To that end, BioMed is willing to lease as little as 5,000 square feet to smaller enterprises. The vacant structures in Ardsley contain a total of 97,000 square feet. Learn More

In May, Thomas Jefferson University opened the doors to a Philadelphia first - the Jefferson Institute for Bioprocessing (JIB). With the potential to help fill the local workforce gap, JIB is the only bioprocessing training institute in the country where students can engage in a range of workshops, training and academic programs modeled after the National Institute for Bioprocessing Research and Training (NIBRT) curriculum. Located in Spring House Innovation Park in Lower Gwynedd, Pennsylvania, the JIB gives scientists, engineers and technicians access to a state-of-the-art bioprocessing training facility where they can practice complex bioprocessing procedures using industry-grade equipment. Learn More

Strides Pharma this week announced that it has acquired a drug manufacturing facility in Riviera Beach, Florida from Micelle BioPharma. The financial details of the deal have Strides paying $500K for the facility and planning to invest upwards of $10 million to expand the sites capabilities. According to published reports, the manufacturing facility has undergone multiple inspections by the U.S. FDA over the years and has no outstanding observations. It joins eight other formulation sites distributed globally that are operated by Strides. Learn More

As it closes in on one of the most valuable land deals in Seattle history, Alexandria Real Estate Equities is betting that biotech can thrive in a real estate market dominated by big tech. The real estate firm recently reached an agreement with the city of Seattle to buy the Mercer Mega Block, a trio of development sites that lie between Amazon's campus and the cluster of life sciences institutions around Lake Union. It's the latest in a long line of bets made by Alexandria on Seattle's life science industry. Alexandria plans to pay $143.5 million for the site, roughly 40 percent above the original bid. Learn More

Pfizer is investing $500 million to expand its manufacturing facility in Sanford, North Carolina, that plays a central role in its efforts to become a major player in gene therapy. The investment will add additional capacity and capabilities to a facility that makes some of Pfizer's most closely watched experimental treatments. The Sanford plant manufactures therapies used for the company's late-stage experimental treatments for Duchenne Muscular Dystrophy (DMD) and hemophilia B therapies, among other gene therapies. It is also responsible for making components for some of Pfizer's vaccines, such as Prevenar 13, which had nearly $6 billion in sales in 2018. Learn More

Caris Life Sciences has unveiled plans to develop the Caris Life Sciences Corporate Park in Irving, Texas, adding to the company's growing footprint in the United States. This new facility will enable approximately 115,000 square feet of new R&D laboratory and office space, and create more than 500 new job opportunities. Within the new Caris Life Sciences Park, employees will work to substantially expand the company's blood-based diagnostic assays as well as blood-based molecular profiling and increase research and development capacity. Learn More

Biopharma will officially open its new blood fractionation facility near the Ukrainian city of Kiev next month. The construction of the site, and subsequent commissioning, took roughly four years to complete and cost $75 million. The plant utilizes industry leading bioprocess solutions from Stilmas, Olsa, GEA Westfalia, General Electric, Pall, and Steriline.  According to published reports, the facility will have three lines for the production of albumin, immunoglobulin, and factor VIII. The processing capacity ranges from 250,000 to one million liters of plasma per year. Learn More

The Colorado Economic Development Commission agreed this week to offer up to $24.8 million in tax and other incentives in hopes of persuading an unnamed biotech company to open a campus in Boulder County and create 1,000 well-paid jobs. According to reports the unidentified company already operates at four sites in Colorado, but if it accepts Colorado's tax credit offer it would consolidate in Boulder County. Estimates value the project at upwards of $130 million. However, other states are being considered as potential locations for the site including Minnesota, Tennessee and Texas. Learn More

Regeneron is planning to build a four-story, 256,000+ sq. ft. structure known as the Science Building at its Tempel Lane campus in Albany, New York. The building, which will house both labs and offices, would be the third and final phase of expansion at Regeneron's campus. The project will be managed by the Boston office of the engineering and construction firm Jacobs. Alert readers will recall that Regeneron has been investing heavily into its Albany site. This includes construction of a 212,000 sq. ft. warehouse and the ongoing project to build a 346,000 sq. ft. manufacturing facility at the site. This latest project is expected to take 30-36 months to complete. Learn More

Aldevron has been granted the $5 million tax break it sought to help facilitate the expansion of its existing facility and the building of a new facility. Specifically, the building of a new, state-of-the-art, 180,000 square foot biologics manufacturing facility and a 20,000 square foot expansion of their existing facility in Fargo, North Dakota. According to published reports, the estimated budget for the project is $72 million, which includes both construction of the buildings as well as procurement of associated equipment. This is a big win for Fargo which faced competition from others seeking to be the site of Aldevon's new facility. Learn More

Cambridge, Massachusetts-based Brammer Bio is planning to set up a new manufacturing facility in Norton, Massachusetts. The Thermo Fisher subsidiary plans to employ 300 staff in its new Norton plant by 2021. While the project is still in the preliminary stages, the cell and gene therapy firm plans to fund the new plant with tax increment financing (TIF), a public financing method used for redevelopment. Brammer currently employs around 600 people in various locations, so will be increasing its staff by 50%. Learn More

Adaptive Biotechnologies has announced plans to lease a new 100,000 sq. ft. corporate headquarters with a state-of-the-art office space and research facility that will triple the company's Seattle footprint.  The biotech's current headquarters, 1551 Eastlake Avenue East, also part of The Eastlake Life Science Campus by Alexandria, is a short distance from the future facility. Shell construction of the new building is expected to be completed in 2020 and Adaptive plans to occupy the new building in 2021 once interior construction is finished. Learn More

CSL has made public plans to move into a new 16 story corporate headquarters, complete with state-of-the art laboratories, near the Parkville biomedical precinct which includes the University of Melbourne, several hospitals and top research facilities such as the Doherty Institute for Infectious Disease. The 376,000 sq. ft. development, which is yet to be given final planning approval, will accommodate more than 800 CSL employees including early stage research and product development teams and its commercial and corporate staff across seven floors of office space and nine floors of laboratories and research and clinical phase production suites. Learn More

HarkerBio is holding a web-based auction today to sell off its collection of biotechnology equipment. The Buffalo-based biotech company ceased operations earlier this year. Its sole secured creditor is the Erie County Industrial Development Agency, which approved the company for a low-interest $500,000 loan. Equipment from industry leading suppliers including Agilent, Bio-Rad, Eppendorf, Thermo Scientific and others are part of this auction.  Learn More

Fujifilm has announced that it has completed the acquisition of Biogen's large-scale biologics manufacturing site located in Hillerød near Copenhagen, Denmark for roughly $890 million in cash. With the closing of this transaction, the Hillerød Manufacturing site is now the fourth biopharmaceutical manufacturing site of FUJIFILM Diosynth Biotechnologies. Hillerød Manufacturing will change its name to FUJIFILM Diosynth Biotechnologies Denmark ApS once all regulatory procedures are complete. The new site consists of a campus hosting a large-scale production facility equipped with 6 x 15,000L bioreactors for the manufacture of cell culture derived biologics for clinical and commercial use. Learn More

Mylan has made public plans to exercise its option to acquire the Novartis manufacturing site at 150 Industrial Road in San Carlos, California. The site, which has had several owners over the last 12 years, was acquired by Novartis with the purchase of Nektar in 2008. The option to acquire the site was obtained by Mylan when it purchased Novartis' cystic fibrosis products for $460 million in 2018. While terms of the deal have not been disclosed, published reports note that Mylan is expected to hire the roughly 100 people employed at the site. Alert readers will recall that Mylan recently agreed to merge with Pfizer's generics business, of which this site will be a part. Learn More

Alexandria made public this week that it is considering developing an up to 650,000-square-foot campus at 5, 10 and 15 Necco St. in Boston's Fort Point neighborhood. The company's leadership, on a conference call this week to discuss earnings, went on to note that construction of the project could begin as early as next year on the biopharma property next to the future world headquarters of GE. Alexandria has invested heavily in the Fort Point area, spending roughly $250 million for a 2.7 acres parcel of land and another $80 million on a parking garage. Learn More

Genmab A/S has signed a long-term lease on a building at 777 Scudders Mill Road in Plainsboro, New Jersey that will serve as its U.S. headquarters office and host research lab. In doing so, Genmab becomes the first new tenant at the campus since the relocation of Bristol-Myers Squibb. Genmab will move into 90,070 square feet across two floors in a consolidation and expansion of its office and research activities in the United States. The 125-acre campus was custom-built for biopharma giant Bristol-Myers Squibb and consists of three, five-story, 220,000-square-foot office buildings. Learn More

Pennsylvania Biotechnology Center's start-up "incubator," which has grown up around Doylestown's Baruch S. Blumberg Institute for cancer and hepatitis research, says it's raising a $50 million investment fund and adding a second, 50,000-square-foot building and a bio-accelerator program to attract new drug and medical device firms to its Bucks County campus.  The fund, dubbed Hatch BioFund Management LLC, will be run by former West Pharma executive turned investment banker Vladimir Walko.  Learn More

Pall Corporation has been chosen by Servier as an exclusive technology and services provider for their Gidy, France biomanufacturing facility. End-to-end solutions from Pall Biotech will be implemented for the development and manufacturing of monoclonal antibodies (mAbs) and recombinant proteins. The facility is part of the Bio-S project at Servier focused on delivering best-in-class support for oncology drug production from research and development (R&D) to clinical scale. The Bio-S project at the Gidy facility includes production lines to support internal production needs with up to 2,000L bioreactor capacity that can be run in a parallel format. Learn More

Precision BioSciences has announced the opening of its production facility for in-house manufacturing. Calling it the Manufacturing Center for Advanced Therapeutics (MCAT), Precision touts the facility as "the first in-house current Good Manufacturing Process (cGMP)-compliant manufacturing facility in the United States dedicated to genome-edited, off-the-shelf chimeric antigen receptor (CAR) T cell therapy products." Currently, the new facility is undergoing CQV (commissioning, qualification, and validation) in preparation for cGMP manufacturing to begin in the fourth quarter of 2019. With the MCAT opening, Precision still has plenty of room to grow. Learn More

A deal-making cancer doctor who sold his biopharma company for almost $12 billion is launching a real estate venture to bolster the growth of the biotechnology industry. Arie Belldegrun's family office, Bellco Capital, has entered into a joint venture with New York-based real estate developer Tishman Speyer to start Breakthrough Properties, the companies said in a statement. The venture said it bought its first property, a 1 acre development site at 105 West First St. in the Seaport District, for $80 million, and is exploring other acquisitions in the area as well as in San Francisco. The Seaport District site comes with 250,000 square feet of development rights and is expected to be finished by 2021. Learn More

Vaxine has made public plans to move into the former VGTI building in Port St. Lucie, Florida. The vaccine lab, owned by the city since 2017, is located along Interstate 95. Port St. Lucie had been marketing the 107,000-square-foot lab as the Florida Center for Bio-Sciences. Vaxine will join the Cleveland Clinic in occupying the facility. While Vaxine is based in Australia, it has three research grants from the National Institutes of Health totaling $7.2 million. One award is for work on a flu vaccine. Another is for a tuberculosis inoculation. Learn More

Nexus Pharmaceuticals has announced an agreement with the village of Pleasant Prairie, Wisconsin to build an industry-leading sterile injectable manufacturing facility. The multi-phase, multi-year project is expected to be completed in ten years, with an estimated investment of $250 million. Construction is planned to commence in August 2019 and is expected to be completed in 2021. The initial phase 1 investment of $85 million will support a new, 100,000 square foot three-story manufacturing facility. The facility is being designed by Integrated Project Services (IPS) with construction management services being provided by Turner Construction. Learn More

Charles River Laboratories has announced the planned opening of the Charles River Accelerator and Development Lab (CRADL™) in South San Francisco in early 2020. CRADL provides flexible, turnkey vivarium rental space supported by Charles River's technical, vivarium, and veterinary support expertise in key biohubs. Initially launched in downtown Cambridge, Massachusetts, CRADL Cambridge offers rental vivarium space for emerging and well-established research institutions. Similar to its sister facility in Cambridge, CRADL South San Francisco will focus on providing a turnkey vivarium solution and in vivo support services for researchers looking to divert more time and resources to their research. Learn More

Alloplex Biotherapeutics, which is working to develop an individualized cellular therapy to treat cancer, is relocating from an incubator at SmartLabs in Cambridge to a 4,700-square-foot facility at TradeCenter 128 in Woburn. The cellular therapeutics company is expected to move in September to the Cummings Properties-managed campus. The landmark TradeCenter 128 campus directly fronts I-95 and is one mile from the I-93 interchange. Several other life science firms-including Quest Diagnostics, OpGen, Batavia Biosciences, and Sophion Biosciences-lease space at this property. Learn More

Citra Labs has unveiled its $30 million, 60,000 square foot, newly renovated manufacturing facility on Messina Drive in Braintree, Massachusetts. The Life Science Corridor Initiative is a partnership created by the mayors of Boston, Cambridge, Quincy, Somerville and Braintree which seeks to bring life science companies to the communities of the Red Line corridor. The communities hope to do this through collaboration with leaders in education, government and life sciences to foster continued success in research, innovation and business development. Learn More

Lonza has announced that it will acquire a sterile drug product fill & finish facility from Novartis. The facility, located in Stein, Switzerland, will be the first for the facility for Lonza's Drug Product Services (DPS). No employees are expected to lose their jobs with the deal. The site will be the first Lonza DPS facility to cover sterile manufacturing for clinical production and commercial launches, the company said. The new facility will help Lonza Pharma & Biotech build on existing parenteral drug product development and testing capabilities. It will be the first sterile drug product fill and finish facility in Lonza's network. Financial terms of the deal were not disclosed. Learn More

Johnson & Johnson has announced the opening of JLABS in Shanghai, the world's largest JLABS and the first in Asia Pacific. The roughly 47,000 sq. ft. facility, located in Shanghai's Zhangjiang Hi-Tech Park, is a collaboration with the Shanghai Pharma Engine Company, Ltd. The site can accommodate more than 50 start-ups across the pharmaceuticals, medical device, consumer and health tech segments, and opens with 31 resident companies, including the three awardees of the Lung Cancer Innovation QuickFire Challenge. Learn More

Mile High Labs, the largest manufacturer of CBD isolate in the world, has announced the purchase of Novartis' 400,000 square foot production facility in Broomfield, Colorado. The transaction includes the land, labs, building, and ready-to-use finished products manufacturing equipment. The Broomfield facility is fully operational, which allows Mile High Labs to begin production in the near term of private label products including tinctures, capsules, tablets, topicals, and gummies. The facility includes equipment and infrastructure for research and development, quality assurance, bottling, filling, packing, warehousing, labeling, shipping and compliance monitoring. Learn More

Selkirk Pharma has made public plans to build a new, roughly $30 million manufacturing facility near Spokane, Washington. The predevelopment application filed with the city of Spokane indicates the company plans to build a 63,000-square-foot manufacturing facility on over 6 acres of land at 9110 W. Granite, in the southwest section of the Pacific Northwest Technology Park, across Granite from the large Northwest Farm Credit Services headquarters building in West Plains, Washington. The manufacturing facility will employ the VarioSys sterile filling system from Bausch+Stroebel and both a Skan isolator and the new Skanfog technology from Skan AG. Learn More

Bristol-Myers Squibb and Catalent have announced that Catalent has agreed to purchase BMS's oral solid, biologics, and sterile product manufacturing and packaging facility in Anagni, Italy. The companies anticipate completing the transaction by the end of 2019, subject to regulatory approvals, the information and consultation procedure with the unions, and the satisfaction of certain other customary closing conditions. Through the years, the Anagni plant has served as one of the primary launch facilities for new medicines from BMS. Upon closing, Catalent will continue to manufacture Bristol-Myers Squibb's current product portfolio at the site. Learn More

AstraZeneca's new global headquarters in Cambridge, UK is now estimated to cost $950 million. That is roughly twice the estimated cost when the project kicked-off several years ago. According to AZ's latest annual report, the increased costs can be attributed to the complexity of the architecture, general inflation in construction costs and "increased investment in new technologies and equipment". While occupancy of the new site was originally planned for 2016, the latest schedule has occupancy starting in 2020 with the site not being fully operational until after 2020. Learn More

KriGen Pharmaceuticals is investing $7 million and hiring 100 employees at its new manufacturing facility and quality control lab in the Harnett County community of Lillington, about 30 miles south of Raleigh. The 55,000-square-foot site is being designed to manufacture a variety of sterile liquid injectable products for hospital and clinical use, using current good manufacturing practices (cGMP) to ensure safety and effectiveness. The North Carolina Biotechnology Center provided expert support in the recruitment of KriGen. Learn More

Tergus Pharma has announced plans to build a state-of-the-art commercial manufacturing facility in the Raleigh-Durham, NC area and will begin construction in July 2019. The new 100,000 square foot facility will have Clinical Trial Material (Phases I thru III) Supplies and commercial manufacturing capabilities and expand current capacity by over 400%. Tergus plans to open the new facility in early 2020, enabling the company to act as a CDMO by providing comprehensive services from development through manufacturing. This expansion comes as Targus announces a partnership with Great Point Partners which will provide the requisite funding. Learn More

A former GSK R&D site near Philadelphia is being redeveloped into a WeWork-styled campus for healthcare and life sciences firms, part of a plan to turn Pennsylvania into a more attractive research hub for the industry. The site was bought last year for a reported $50 million, and spans 1.6 million square feet. The bulk of that is in Upper Merion, where GSK has leased back space, while 640,000 square feet will be dedicated as a "coworking ecosystem."  Efforts to establish new R&D centers outside of the industry's traditional hubs in the Bay Area near San Francisco and Cambridge, Massachusetts, have been mostly mixed. Learn More

FUJIFILM has announced an initial $10 million investment to establish a full scale, fully integrated continuous processing facility for non-GMP manufacture of biopharmaceuticals at its FUJIFILM Diosynth Biotechnologies, Billingham, UK location. This perfusion-based facility represents the culmination of 3 years of in-house innovation by Fujifilm group companies and includes the introduction of patented, disruptive downstream bioprocessing technology to the biopharmaceutical industry. The new facility will include a 500L single use perfusion bioreactor and 7 patented downstream processing units which are expected to be available for process development services this Fall. Learn More

KD Pharma has acquired a manufacturing facility in Seal Sands, UK to manufacture omega-3 products. The site, which joins KD sites in Germany, Norway and the U.S., was previously used for manufacturing omega-3 products so is well positioned to be brought online later this year. The acquisition will enable KD Pharma to meet market demand for APIs in response to new product approvals, label expansions and clinical research. "This acquisition expands our technology and manufacturing base for producing APIs with the highest concentrations of EPA and DHA omega-3s," said Oscar Groet, KD Pharma Group's chief executive. Learn More

Aldevron has announced plans to build a 14-acre gene therapy manufacturing campus at its headquarters in Fargo, North Dakota. Phase one of the construction project will start in August. Once completed, its annual capacity will be more than $1 billion of plasmid DNA, RNA, gene editing enzymes and other biologics. The expansion will increase biotech production capacity 10-fold, grow its warehouse space by more than four times, and develop a research and development center. The new construction will include three new buildings totaling 189,000 square feet. The first building is expected to be fully operational by the first quarter of 2021. Learn More

Iovance Biotherapeutics announced this week that it will build a 136,000-square-foot facility in Philadelphia to produce cancer therapies using its tumor-infiltrating lymphocyte (TIL) technology. While construction will take about two years, the California biotech expects to spend some $75 million over three years on the overall project, creating "several hundred" jobs in Philadelphia. Iovance received undisclosed financial incentives from the state, city and PIDC, a public-private economic development corporation, for the new site. It also has a letter of intent from PIDC for a five-year option to expand further. Learn More

Longmont city council members this week voted their unanimous initial approval of an ordinance authorizing the offer of an estimated $1.9 million in incentives to AveXis to get the company to expand its presence in Longmont. AveXis, a subsidiary of Novartis, recently bought the 64.12-acre former AstraZeneca property at 4000 Nelson Road, rehired 150 full-time former AstraZeneca employees and has begun operations there. Longmont's proposed $1.9 million incentives package would include rebates on certain costs and taxes on property, machinery and equipment.
Learn More

Boehringer Ingelheim has announced a multi-million-dollar investment that will see the expansion of its manufacturing capacity in Mexico over the next two years. The majority of the investment, $52 million will be at the biopharma giants site in Xochimilco which specializes in oral dosage anti-diabetic drugs. The Xochimilco plant is one of three sites that Boehringer has in Mexico, and the capital injection will be destined to increase the production capacity by at least 50%. The expansion at the Xochimilco plant is part of an investment plan to invest $84 million by 2023 to boost production at all three of its production sites in the country. Learn More

Chugai, a business unit of Roche, announced this week a decision to construct a centralized research laboratory. The new facility, to be known as the Chugai Life Science Park, is being constructed in Yokohama. The new facility will become home to both the Fuji Gotemba Research Laboratories and Kamakura Research Laboratories upon its completion. As for the future of the two research labs, both will be closed after the consolidation is complete. The new 380,000 sq. ft. facility is expected to cost roughly $1.15B with construction scheduled to begin in August of this year and be completed in Q3' 2022. Learn More

WuXi Biologics has announced that it has entered into a strategic partnership Letter of Intent (LOI) with a global vaccine leader, pursuant to which WuXi Vaccines will build a dedicated facility and supply a commercial product for the global market. Under the LOI, WuXi Vaccines will build an integrated vaccine manufacturing facility including drug substance manufacturing (DS), drug product manufacturing (DP) as well as Quality Control labs (QC). The facility will be dedicated to manufacture 100% of the global market of one of our partner's vaccine products. The value of the 20-year manufacturing contract is estimated to be more than $3 billion USD. Learn More

The University of Maryland BioPark is planning its next building as developer Wexford Science & Technology has revealed plans for a $200-plus million, 10-story, 333,000 sq. ft. office and biotech building at the northwest corner of Martin Luther King Blvd. and W. Baltimore St. The new building is Phase One of a two-phrase project that will redevelop a Poppleton/Hollins Market block that borders Martin Luther King Blvd., W. Baltimore St., W. Fayette St., and N. Fremont Ave. The project site currently includes green spaces, a parking lot, and several open spaces created by demolishing a Chinese carryout restaurant, rowhomes, and a former church. Learn More

Celltion Chairman Seo Jung-jin has announced that the biopharma group will invest roughly $34 billion and create some 110,000 jobs by 2030. These monies will be distributed so as to provide roughly $23 billion for its biopharma business, $4 billion for its APIs business and $7 billion for its U-Healthcare platform business which involves artificial intelligence and medical database services. The stated purpose of which being to build a bio-industrial valley capable of making South Korea the hub of the global biopharma industry. To realize this business plan, Celltrion says it will hire some 2,000 R&D professionals and 8,000 others for its expanded factories. Learn More

Thermo Fisher Scientific announced this week that it has entered into a definitive agreement to acquire a drug substance manufacturing site in Cork, Ireland, from GSK for approximately $100 million in cash. The Cork site will expand capacity to meet customer demand for the development and commercial manufacturing of complex APIs. Thermo Fisher will continue to produce APIs for GSK under a multi-year supply agreement and plans to expand use of the site to develop and produce complex APIs for other customers as well. The site contains 270,000 liters of reactor capacity, 10 production buildings, an R&D pilot plant and lab infrastructure. Learn More

The Delaware Biotechnology Institute will expand into 70,000 square feet within the new six-story, $160 million Biopharmaceutical Innovation Building on the STAR Campus next February. The building, which includes labs, offices, collaborative space, and shared research facilities, will be the home of the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL), a coalition of 150 companies, educational institutions, nonprofits and state governments. The Delaware Biotechnology Institute will take a little over two floors of the six-story building besides the 70,000 square feet it has in its current location at 15 Innovation Way. Learn More

ElevateBio has announced plans to create and build a broad portfolio of single and multi-product cell and gene therapy companies. Leveraging the roughly $150 million it has raised to date, Elevate Bio plans to provide centralized bench-to-bedside capabilities including world-class scientists, manufacturing facilities, drug development and commercialization expertise. All of which will be housed in a new 100,000 sq. ft. R&D and Manufacturing center in Waltham, Massachusetts to be known as BaseCamp which is on schedule to be fully operational in Q3/Q4 of 2020.  In the meantime, the company is leveraging its lab space in Cambridge, Massachusetts to launch collaborations. Learn More

Bayer has made public plans to invest $150 million into its site in Berekeley, CA to build a Cell Culture Technology Center. The new Cell Culture Technology Center will be built on Bayer's existing Berkeley campus. The new 40,000 square foot facility, which is expected to be ready for clinical production in late 2021, will support the development of emerging therapies in Bayer's portfolio with an emphasis on oncology, cardiology and additional specialty care therapeutic areas. Bayer has selected Fluor for design and construction, and GE Healthcare for the integration of its FlexFactory™ technology platform into the Center. Learn More

Merck & Co., Inc., a publicly held global healthcare company known as MSD outside the United States and Canada, plans to invest up to $1 billion in stages over the next three years to expand its manufacturing operation in Elkton, Virginia. The company will add 120,000 square feet to its existing 1.1 million-square-foot operation in Elkton, Virginia to increase production of its Human Papillomavirus vaccines. Virginia successfully competed with other states for the project, which is anticipated to create approximately 100 new jobs in Rockingham County. As part of the expansion Blue Ridge Community College and James Madison University will collaborate to address Merck's short- and long-term workforce needs. Learn More

The Centre for Process Innovation (CPI) has collaborated on a project to develop new research and testing capabilities to drive further scale-up and manufacture of next generation liquid formulated products. Working alongside the Universities of Birmingham, Leeds and Edinburgh, CPI has created an open-access facility to enhance SME and larger corporate partners' product development. Consisting of a series of scaled vessels, from one liter to 1,000 liters, with a sample flow loop to allow in-line and at-line monitoring of process parameters, the facility's configuration is highly flexible and can be adjusted to specific project needs. Learn More

Biotechnology company Aldevron is expanding its Madison site, more than doubling the size of its space and, potentially, its staff over the next couple of years. The company currently occupies 8,000 square feet at 5602 Research Park Blvd., in University Research Park, and it will add nearly 10,000 square feet, moving into space being vacated by another biotech. Large fermentation equipment already has arrived to expand the site's biomanufacturing capacity. Aldevron's Madison labs culture bacteria, as well as mammal and insect cells, to manufacture proteins and enzymes. The expansion is expected to be completed and operating by this fall. Learn More

Takeda announced this week that it has opened a new research facility in San Diego. The new 165,000 square foot site is home to more than 250 employees focused on leveraging specialized drug discovery technologies and advancing discovery research in gastroenterology and neuroscience, the company said. In its announcement, Takeda said the San Diego site is home to four research platform groups -- structural biology, early target discovery, computational biology and biologics. The new San Diego facility complements Takeda's global Research & Development center in Cambridge, Mass. and its other global research site in Shonan, Japan. Learn More

Fujifilm Diosynth Biotechnologies has announced an expansion to its Billingham, United Kingdom location through the creation of a new BioCampus. The initial phase of this project will involve a new purpose-built facility. This will consist of approximately 42,000 square feet of space and will house roughly 250 existing staff and 50 new staffers. This latest investment is part of a major strategic growth plan. In September 2017 FDB announced the opening of the 10,000 square foot, state-of-the-art cell culture PD Labs in Wilton Centre, Teesside. In January 2019, the Wilton Laboratories were further expanded with the addition of 7,000 square feet of laboratory space increasing FDB's cell culture PD capacity. Learn More

Precigen this week announced the official opening of its new 5,000 sq. ft. manufacturing facility to support gene therapy manufacturing. The GMP facility was designed with agility and control in mind, focusing on rapid manufacturing and the ability to scale production appropriately to meet early stage clinical trial needs. The facility includes ISO 7 cleanroom suites that will be utilized to manufacture gene therapy vectors, as well as cell banks for early stage gene therapy trials. Due to the flexible design, other types of cell-based biopharma products can also be manufactured in the facility. Additionally, the facility includes a GMP quality control laboratory that supports lot release and stability testing. Learn More

GlaxoSmithKline has announced plans to spend $100 million to expand capacity at its Hamilton, Montana, site and boost production of vaccines, including Shingrix. The investment will create temporary construction and contracting jobs and a range of new permanent positions in science, engineering, manufacturing and quality control according to GSK. The biopharma giant is focusing the investment on components for adjuvants, which are added to vaccines to strengthen the immune response of patients. GSK is one of the few remaining large pharmaceutical makers in the vaccine market, along with Pfizer and Merck & Co. Learn More